Pretreatment mortality risk prediction model in patients with polymyositis/dermatomyositis-associated interstitial lung disease

We developed and validated an evidence-based mortality risk prediction model with simple, readily accessible clinical variables in patients with PM/DM-ILD, which may inform clinical decision-making.